Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome

Swenson, J. Robert; O’Connor, Christopher M.; Barton, David; Zyl, Louis T. van; Swedberg, Karl; Forman, Leslie; Gaffney, Michael; Glassman, Alexander H.

doi:10.1016/j.amjcard.2003.08.006

Cited by 116 publications

(77 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16,27 Given our findings, there is a need to further explore the association of depressive symptoms with prognosis, patients' health status, and to identify potential underlying mechanisms and uses of this information in designing strategies to maximize PAD patients' health status outcomes. 28 Several limitations should be considered when interpreting our findings. First, this is a prospective, single-center registry of patients undergoing PTA only.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits

et al. 2011

View full text Add to dashboard Cite

Depressive symptoms are known to compromise health status in cardiac disease, but this relationship has not been described in peripheral artery disease (PAD). Depressive symptoms (PHQ-9) and disease-specific health status (Peripheral Artery Questionnaire, PAQ) were assessed in 242 PAD patients undergoing percutaneous transluminal angioplasty (PTA) at baseline and 1 year. Patients were classified by baseline and follow-up depression status (moderate-severe depressive symptoms = PHQ ≥ 10). Changes were categorized as no depression/improvement of depression versus persistent/worsened depression. At baseline, 20% of patients were depressed; at 1 year, 17% of patients experienced persistent/worsened depression. Although this group improved on most PAQ subscales, they improved to a significantly lesser degree than those without depressive symptoms or those who improved by 1 year (p-values < 0.05). Baseline depressive symptoms (B per 5-point increment = -11.9, 95% CI -15.3, -8.5, p < 0.0001) and changes in depression were independently associated with a decrease in 1-year health status (B per 5-point increment = -11.7, 95% CI -14.3, -9.2, p < 0.0001).In conclusion, depressive symptoms are associated with less improvement in health status 1 year after undergoing a peripheral endovascular revascularization (PER) as compared with those having no depression or whose depressive symptoms improve. Efforts to improve depression detection and treatment among patients with PAD may improve the health status outcomes of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits

et al. 2011

View full text Add to dashboard Cite

show abstract

“…SSRIs generally do not slow cardiac conduction, cause orthostatic hypotension, decrease heart rate variability, or alter QT variability measures (9,14). In regard to treatment, SSRIs appear to be safe for use in cardiac patients and can improve both depressive symptoms and quality of life (17,36,46).…”

Section: Discussionmentioning

confidence: 99%

σ₁-Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice

Tagashira

Bhuiyan

Shioda

et al. 2010

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRIs) are known to reduce post-myocardial infarction-induced morbidity and mortality. However, the molecular mechanism underlying SSRI-induced cardioprotection remains unclear. Here, we investigated the role of σ1-receptor (σ1R) stimulation with fluvoxamine on myocardial hypertrophy and cardiac functional recovery. Male ICR mice were subjected to transverse aortic constriction (TAC) in the cardiac aortic arch. To confirm the cardioprotective role of fluvoxamine by σ1R stimulation, we treated mice with fluvoxamine (0.5 or 1 mg/kg) orally once per day for 4 wk after the onset of aortic banding. Interestingly, in untreated mice, σ1R expression in the left ventricle (LV) decreased significantly over the 4 wk as TAC-induced hypertrophy increased. In contrast, fluvoxamine administration significantly attenuated TAC-induced myocardial hypertrophy concomitant with recovery of σ1R expression in the LV. Fluvoxamine also attenuated hypertrophy-induced impaired LV fractional shortening. The fluvoxamine cardioprotective effect was nullified by treatment with a σ1R antagonist [NE-100 (1 mg/kg)]. Importantly, another SSRI with very low affinity for σ1Rs, paroxetine, did not elicit antihypertrophic effects in TAC mice and cultured cardiomyocytes. Fluvoxamine treatment significantly restored TAC-induced impaired Akt and endothelial nitric oxide synthase (eNOS) phosphorylation in the LV. Our findings suggest that fluvoxamine protects against TAC-induced cardiac dysfunction via upregulated σ1R expression and stimulation of σ1R-mediated Akt-eNOS signaling in mice. This is the first report of a potential role for σ1R stimulation by fluvoxamine in attenuating cardiac hypertrophy and restoring contractility in TAC mice.

show abstract

“…As pointed out by Ketterer and colleagues, if a given risk factor cannot be modified, irrespective of whether it is causal, it has no clinical utility [55]. Although recent intervention trials targeting other psychosocial risk factors have shown mixed results, such as the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study [56], the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) [57,58], and the randomized Exhaustion Intervention Trial (EXIT) [59], there is suggestive evidence from these and other trials that a reduction in negative emotions may lead to improved prognosis [60,61]. Although social inhibition may be less amenable to change, it is important to note that a reduction in negative affectivity (below the standardized cut-off of 10) would make the difference between whether a patient is classified as Type D or not.…”

Section: Recommendations and Conclusionmentioning

confidence: 99%

Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups

Pedersen¹,

Denollet²

2006

CCR

128

130

View full text Add to dashboard Cite

Abstract:The distressed personality (Type D) is an emerging risk factor in cardiovascular disease (CVD) that incurs a risk on par with left ventricular dysfunction in patients with ischemic heart disease. Type D is defined as the co-occurring tendencies to experience increased negative emotions and to inhibit self-expression in social interactions. Evidence is accumulating that Type D may also be a risk factor for adverse outcome across CVD patient groups, including patients undergoing revascularization with drug-eluting stent implantation or bypass surgery, patients with heart failure, peripheral arterial disease, and arrhythmia. In these patient groups, Type D personality has been associated with a 2-5 fold increased risk of adverse prognosis, impaired quality of life and symptoms of anxiety and depression independent of traditional biomedical risk factors, including disease severity. Although little is known about the pathways responsible for the detrimental effects of Type D on clinical outcome, the immune system and health-related behaviors, such as smoking and noncompliance, are likely candidates. Further research is warranted to investigate whether Type D personality is here to stay as a risk factor for CVD, but weighing current evidence on Type D against a set of external criteria shows that Type D personality fulfills the majority of these criteria. Importantly, Type D can easily be assessed in clinical research and practice with the standardized and validated DS14.

show abstract

Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome

Cited by 116 publications

References 18 publications

Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits

Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits

σ₁-Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice

Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups

Contact Info

Product

Resources

About

Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome

Cited by 116 publications

References 18 publications

Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits

Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits

σ1-Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice

Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups

Contact Info

Product

Resources

About

σ₁-Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice